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In Drosophila species, molecular asymmetries guiding embryonic development are established maternally.
Vasa, a DEAD-box RNA helicase, accumulates in the posterior pole plasm, where it is required for embryonic
germ cell specification. Maintenance of Vasa at the posterior pole requires the deubiquitinating enzyme Fat
facets, which protects Vasa from degradation. Here, we found that Gustavus (Gus) and Fsn, two ubiquitin
Cullin-RING E3 ligase specificity receptors, bind to the same motif on Vasa through their paralogous B30.2/
SPRY domains. Both Gus and Fsn accumulate in the pole plasm in a Vasa-dependent manner. Posterior Vasa
accumulation is precocious in Fsn mutant oocytes; Fsn overexpression reduces ovarian Vasa levels, and
embryos from Fsn-overexpressing females form fewer primordial germ cells (PGCs); thus, Fsn destabilizes
Vasa. In contrast, endogenous Gus may promote Vasa activity in the pole plasm, as gus females produce
embryos with fewer PGCs, and posterior accumulation of Vas is delayed in gus mutant oocytes that also lack
one copy of cullin-5. We propose that Fsn- and Gus-containing E3 ligase complexes contribute to establishing
a fine-tuned steady state of Vasa ubiquitination that influences the kinetics of posterior Vasa deployment.
Establishment and maintenance of polarity is essential for
multicellular development. Asymmetric distribution of pro-
teins within cells is often realized by localizing specific mRNAs
to distinct positions and by tightly regulating their translation
(1). During Drosophila oogenesis, polarized deployment of key
mRNAs is crucial for the maternal determination of the em-
bryonic body axes (17). However, although asymmetric mRNA
localization within cells is widespread (1, 22), some proteins
localize directly. An example is Vasa (Vas), which accumulates
in a highly polarized fashion in Drosophila oocytes from a
uniformly distributed mRNA that is not believed to be under
translational control (8, 20, 21). Vas accumulates in the pole
plasm of the oocyte, where it is necessary for embryonic pos-
terior patterning and primordial germ cell (PGC) formation
(26). Accumulation of high levels of Vas in the pole plasm
requires the deubiquitinating enzyme (DUB) Fat facets (Faf)
(25). In faf mutants, levels of posterior Vas are reduced, and
polyubiquitinated forms of Vas accumulate. This indicates that
Vas stability in the pole plasm is regulated by ubiquitin-depen-
dent pathways.
Ubiquitination culminates in the E3 ligase-catalyzed forma-
tion of a covalent bond between the C terminus of ubiquitin
and a lysine residue of the ubiquitinated protein (12). Target
proteins can be ubiquitinated simultaneously and/or sequen-
tially on different lysine residues, and the presence of seven
internal lysine residues in ubiquitin itself allows for the forma-
tion of topologically distinct polyubiquitin chains (9, 12, 27).
Different forms of ubiquitination usually produce different ef-
fects on the target protein, and modulation of the steady-state
dynamics of ubiquitin conjugation can strongly influence a
target’s activity and/or stability. The regulatory logic governing
the steady state of target ubiquitination can consist of nonlin-
ear pathways that involve feedback mechanisms, responses to
cellular stimuli such as phosphorylation, and complex cross-
regulation between individual components of the ubiquitin
conjugation machinery and corresponding DUBs.
Cullin-RING ubiquitin E3 ligases (CRLs) comprise the larg-
est class of ubiquitin E3 ligases (30). CRLs contain a substrate
specificity receptor that binds the ubiquitinated target and a
RING protein that is involved in recruiting an E2-conjugating
enzyme, which catalyzes transfer of ubiquitin to the associated
substrate through the E3 ligase. RING proteins and particular
substrate specificity receptors are brought together by scaffold
proteins called Cullins, often through small adaptor proteins
that link the Cullin with the receptor. Cullin-1 (Cul-1) CRLs
recruit their substrate through F-box proteins, with a Skp fam-
ily adaptor protein forming a bridge between the Cullin and
the F-box. In contrast, CRLs containing Cullin-5 (Cul-5) rec-
ognize their substrates through receptor proteins that contain
a SOCS-box, which are linked to the Cullin by the Elongin
B/Elongin C (EloBC) adaptor complex.
In this study we identified the F-box protein Fsn and the
SOCS-box protein Gus as in vivo regulators of Vas. Fsn and its
Caenorhabditis elegans orthologue are required for normal syn-
aptic development and associate with RING proteins encoded
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by highwire and rpm-1, respectively (24, 46). Gus was previously
shown to interact with Vas and was implicated in its posterior
localization (37). Gus features a B30.2/SPRY domain through
which it directly interacts with a five-amino-acid motif on Vas
(DINNN), and it can be cocrystallized with the EloBC complex
(44, 45). Fsn has a B30.2/SPRY domain that is very similar to
that of Gus (40% identity). We show experimentally that Fsn
also binds the DINNN motif and that Gus associates more
stably with Vas than does Fsn. Using genetic methods, we
investigated the contributions of Gus and Fsn to regulating
Vas activity and deployment.
MATERIALS AND METHODS
Structural predictions. The amino acid sequences of the B30.2/SPRY domains
of Gus and Fsn were aligned using ClustalW (19) and introduced into the
MODELLER program (32). The B30.2/SPRY domain of Fsn was modeled using
the previously solved structures of Gus bound to the Vas peptide (protein
database [PDB] code 2IHS) (Fig. 1A to D) (45) and of Gus in complex with
EloBC (PDB code 2FNJ) (44 and data not shown).
Transgenic fly strains. Transgenes encoding green fluorescent protein (GFP)-
tagged Vas (GFP::Vas) were generated as described previously (10), except that
site-directed mutagenesis was performed using GeneTailor (Invitrogen). Fsn and
Gus fusion proteins were produced by PCR amplification of the full-length open
reading frames (ORFs) of Fsn, GusL, and GusS from the Berkeley Drosophila
Genome Project Drosophila gene collection (BDGP DGC) cDNA clones
LD47425 and LD34464, respectively, and then cloning the products into pENTR/
D-TOPO (Invitrogen). When applicable, mutations were introduced at this step
using GeneTailor (Invitrogen). Positive clones were then recombined with pPVW
and pPWH (Drosophila Gateway collection, provided by the Murphy lab) to
produce Venus::Fsn (V::Fsn), Venus::GusL (V::GusL), Venus::GusS (V::GusS),
Fsn::hemagglutinin (Fsn::HA), GusL::HA, and GusS::HA. Standard procedures
were used to transform the constructs into flies and to map the insertion chro-
mosomes. Expression of the transgenic proteins was achieved by crossing to the
appropriate Gal4 driver strains.
Fly stocks. gusf04367, cul-5EY32463, Df(2L)nap1, and Df(2L)Exel7124 were pro-
vided by the Bloomington Stock Center, Fsnf06595, gusf07073, and guse00456 were
from the Exelixis Collection (Harvard Medical School).
Hatching assays and PGC counts. Virgin females were collected for 3 days and
then mated to Oregon-R males for 24 h. Subsequently, embryos were repeatedly
collected, and the number of hatched and unhatched embryos was determined 36
to 48 h after each egg lay. For PGC counts, embryos were fixed and immuno-
stained with anti-Vas antibodies. PGCs were counted in stage 10 embryos at
200 magnification.
Immunoprecipitations. Immunoprecipitations were performed as described in
reference 16, using agarose-coupled mouse monoclonal anti-HA or rabbit anti-
Vas antibodies. HA-tagged transgenic proteins were expressed in the ovaries
under the control of the nanos-Gal4::VP16 driver (41). Rabbit or agarose-cou-
pled mouse immunoglobulin G (IgG) (Santa Cruz) was used as control. For
peptide competition assays, 10 l water or 10 l of a 1-mg/ml aqueous solution
of the indicated peptides (45) was added to each immunoprecipitation reaction
mixture. Western blots of the immunoprecipitates were probed with rabbit or rat
anti-Vas antibodies (1:10,000), horseradish peroxidase (HRP)-coupled rat
anti-HA antibodies (Roche; 1:2,000), rabbit anti-Cullin-1 antibodies (Zymed;
1:250), or rabbit anti-Cullin-5 antibodies (1:200) (31).
Immunocytochemistry. Immunocytochemistry was performed using standard
procedures. Rabbit and rat anti-Vas antibodies were used at 1:2,000 and detected
with AlexaFluor-488 or AlexaFluor-555 after mounting in Antifade (Molecular
Probes). Ovaries expressing GFP or Venus fusion transgenes were treated like-
wise. Images were taken on LSM510meta confocal microscopes (Zeiss); analysis
and processing were done with ImageJ, LSM image browser, and Adobe Pho-
toshop. Embryos derived from mothers expressing GFP-Vas in a vas mutant
background were collected, dechorionated with 50% bleach for 2 min, and
imaged live.
Preparation of ovarian extracts for Western blot analysis. Ovaries were dis-
sected into phosphate-buffered saline (PBS) and frozen in liquid nitrogen. Sam-
ples were homogenized in cold hybridization buffer (HB) (1 PBS with 10
Roche EDTA-free protease inhibitor cocktail) and cleared by centrifugation at
20,000  g for 10 min. The supernatant was recovered, its protein concentration
was determined by a Bradford assay (Bio-Rad), and the remaining sample was
boiled with an equal volume of 2 sodium dodecyl sulfate (SDS) loading buffer
(33). Samples were then diluted with 1 SDS loading buffer to the desired final
concentration and boiled again before being loaded onto polyacrylamide gel
electrophoresis (PAGE) gels. We dissected 15 to 35 ovaries from 24- to 48-h-old
females per sample. We noted that Df(2R)Exel7124/Fsnf06595 ovaries were often
smaller and contained fewer late-stage egg chambers than those of other geno-
types of comparable age. Therefore, to ensure comparability we chose only
well-developed Fsn mutant ovaries that most closely resembled those of other
genotypes for analysis.
Quantitative Western blot analysis. Ovarian extracts were diluted to a final
concentration of typically 0.33 mg/ml (in our initial experiments we performed
serial dilutions to determine and ensure the linear range of our detection
method), and 15 l was loaded per lane onto 6% E-PAGE gels (Invitrogen). We
tested six genotypes per 96-well gel, such that each extract was loaded in eight
replicates with eight adjacent wild-type control extracts in a sextant of the gel.
We ran at least three independent extracts, generating 32 sample/control data
points, per tested genotype (except for vasPH165/vasPD, only one extract was used
for negative control purposes). After running the extracts, gels were equilibrated
in transfer buffer (2.5 mM Tris, 19.2 mM glycine, 20% MeOH) for 30 min of
shaking and then wet transferred onto activated Hybond-LFP membranes at 25
V at 4°C overnight. Membranes were then developed at room temperature.
Following blocking with 2% ECL-Advance blocking agent (GE Healthcare) in
PBST (1 PBS, 0.2% Tween 20) for 1 h, membranes were rinsed two times in
PBST, washed two times with PBST for 5 min, and incubated with duplexed
primary antibodies in blocking solution for 1.5 h. Primary antibodies were rabbit
anti-Vas antibodies (rabbit 3005) at 1:4,000 and mouse anti--tubulin antibodies
(Sigma, clone DM1A) at 1:2,500. Membranes were then rinsed two times,
washed two times with PBST for at least 5 min each, and subsequently incubated
with duplexed Cy3-conjugated anti-mouse and Cy5-conjugated anti-rabbit anti-
bodies (GE Healthcare; 1:1,250) for 1 h. Membranes were then rinsed three
times with PBST, washed with PBST four times for at least 5 min each, rinsed
three times with PBS, and dried in the dark overnight at room temperature or for
1 h at 37°C. Blots were scanned with a Typhoon Trio and analyzed using
ImageQuant. For each sextant, the Cy5 and Cy3 signal of one wild-type lane was
set arbitrarily to 100%. Subsequently, we calculated the relative amount of Vas,
standardized to -tubulin, in our test genotype in comparison to its control by
using the following equation:
Cvas
1
n
 n
ICy5
ICy3

sample lane
ICy5ICy3control lane
 100
where I is the normalized fluorescence intensity of a given band and n is the
number of paired control/test lanes. The graph presents the average of all pooled
data points obtained for each genotype; error bars denote the standard devia-
tions (SD).
To quantitate GFP::Vas levels, we produced Western blots of ovarian extracts
which were separated on SDS mini gels in a dilution series. Subsequent to
probing the membranes as described above, we normalized each GFP::Vas/-tubu-
lin signal ratio of the transgene of GFP::Vas(5xAla) (a GFP-Vas fusion with a
DINNN motif substituted by five Ala residues) to that of GFP::Vas(wt) (the wild-
type GFP-Vas fusion). Four independent extracts were compared in four dilution
steps each.
Quantitative reverse transcription-PCR (qRT-PCR). To assess the effect of
the PBac insertions on the expression of gus and Fsn, ovarian RNA was isolated
from 15 females using the RNeasy kit (Qiagen) and reverse transcribed using
SuperScript II (Invitrogen) following the supplier’s instructions. Intron-spanning
primers were used in PCR analyses with Taq polymerase (Qiagen) according to
the manufacturer’s recommendations.
Expression levels of GFP::Vas transgenes were assessed as follows: ovarian
RNA was isolated with RNeasy, including on-column digestion of contaminating
DNA with the RNase-free DNase kit (Qiagen). Total RNA (0.8 g) was used for
reverse transcription and quantitative PCR (qPCR) using the DyNAmo cDNA
synthesis kit and qPCR kit (Finnzymes), following the supplier’s recommenda-
tions. Transgenic RNA was quantified on a Bio-Rad CFX98 system using a
GFP-specific and a vas-specific primer. Rp49-, -tubulin-, and cul-1-specific
primer pairs were used for normalization. Data were analyzed using the Bio-Rad
CFX Manager software. All reactions were performed in triplicates of two
independently isolated RNA samples per genotype.
1770 KUGLER ET AL. MOL. CELL. BIOL.
 o
n
 M
ay 7, 2015 by PO
STECH LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
FIG. 1. Gus and Fsn are Vas-interacting proteins. (A) Sequence alignment of the SPRY domains of Gus and Fsn. Identical and similar residues are
highlighted in red and pink, respectively. Inverted triangles highlight the residues that form the Vas binding pocket. The red inverted triangle marks the
residue W221 of Gus and Y239 of Fsn. (B) Surface view of a Gus crystal structure (PDB code 2IHS) (44). Surface residues conserved between Gus and
Fsn are colored as described for panel A. (C to F) The B30.2/SPRY domains of Gus and Fsn are likely to form highly similar 3D structures. Panels C
and E show crystal structures obtained from Gus (cyan) in complex with a Vas fragment (yellow) (PDB code 2IHS) (45). Panels D and F are structural
predictions of the B30.2/SPRY domain of Fsn onto the crystals shown in panels C and E, respectively. The surface topology of the predicted Vas-binding
site on Fsn (F) is almost identical to that of Gus (E). (G) Peptides used for the competition experiments shown in panels H and I. Kd values (apparent
dissociation constants) for the interactions between Gus and peptides (45) are shown. (H) Fsn::HA and Vas coimmunoprecipitate. The interaction is
sensitive to competition with peptides containing an intact DINNN motif. (I) GusL::HA and Vas coimmunoprecipitate. While the interaction is sensitive
to peptide competition, the effects are much less pronounced than is the case for Fsn. (J) Both the wild type and W221L mutant Gus::HA associate with
Vas in coimmunoprecipitation experiments; however, the amino acid substitution reduces the affinity of the interaction. All transgenic lines expressing
GusL::HAW221L produced low levels of protein, possibly indicating a destabilizing effect of the substitution. Two transgenic lines are shown for
Gus::HAW221L (second and fourth panels from the top), both compared to the same Gus::HA strain that expressed at a similar level to the mutant protein
(first and third panels). (K) Unlike wild-type Fsn::HA, transgenic Fsn containing the Y239A mutation does not detectably coimmunoprecipitate with Vas.
Two independent transgenic lines for each protein are shown.
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RESULTS
Structural predictions suggest a similar mode of interaction
of Gus and Fsn with Vas. The SPRY domain of Gus forms a
rigid surface pocket which embeds the DINNN motif of Vas
(42, 43). Cocrystalization studies of SSB proteins, the mamma-
lian orthologues of Gus, with a Vas peptide revealed that their
SPRY domains feature very similar Vas-binding pockets (see
Fig. S1A in the supplemental material) (15). Drosophila Fsn
contains a SPRY domain that is also very similar to those of
Gus (Fig. 1A and B) and the SSB family members (see Fig.
S1B in the supplemental material). We modeled the B30.2/
SPRY domain of Fsn onto the existing Gus structures that
were derived by X-ray crystallography (Fig. 1C to F and data
not shown) (44, 45). As predicted by the sequence similarity,
the overall organization of the predicted B30.2/SPRY domain
structure of Fsn is almost identical to that of Gus. Moreover,
the surface topology as well as the position and identity of most
of the amino acids implicated in Gus-Vas interaction are con-
served in the predicted Fsn structure. As expected, the pre-
dicted Fsn structure is also highly similar to the structure of the
SSB proteins (see Fig. S1C in the supplemental material).
These predictions suggest that Fsn would associate with Vas in
a manner that is structurally similar to Gus, which we pro-
ceeded to test experimentally.
Gus and Fsn interact with a common site on Vas. To directly
test whether Fsn is a Vas-interacting protein and to further
characterize the Vas-Gus interaction in vivo, we generated trans-
genic flies that express HA-tagged versions of Gus (GusL::HA;
see below) or Fsn (Fsn::HA) upon Gal4 induction. We then
immunoprecipitated Vas from ovarian extracts expressing ei-
ther transgene in the germ line and found that both Fsn::HA
and GusL::HA efficiently copurified with Vas (Fig. 1H and I,
lane 1). Vas also copurified with GusL::HA and Fsn::HA in the
reciprocal experiment using anti-HA resin (data not shown).
The interactions persist even in modified radioimmunoprecipi-
tation (mRIPA) buffers with high concentrations of detergents
(see Materials and Methods). Thus, both Gus and Fsn can
form protein complexes with Vas in ovaries.
Short peptides derived from Vas that contain an intact
DINNN motif bind to Gus (45). Similar peptides (Fig. 1G)
efficiently competed with Vas for interaction with Fsn::HA
(Fig. 1H, lanes 2 and 4), indicating that the Fsn-Vas interaction
likely occurs through direct binding to the DINNN motif. To
confirm the relevance of the DINNN motif of Vas for binding
to Gus or Fsn, we assessed peptides with single-amino-acid
substitutions within or outside the DINNN motif for their
ability to compete with these interactions (Fig. 1G). Substitu-
tion of either of two DINNN residues (N187 or N188) with Ala
greatly reduced affinity of Vas for Gus (45), and peptides with
these substitutions failed to compete with the Vas-Fsn::HA
interactions (Fig. 1H, lanes 3 and 6). Substitution of D184,
another residue included in the DINNN motif, with Ala more
modestly reduced the affinity of Vas for Gus (45), and this
peptide acted more weakly as a competitor with Vas for bind-
ing to Fsn::HA (Fig. 1F, lane 5). In contrast, substitution of
N189, a residue outside the DINNN motif, with Ala had no
impact on the affinity of the mutant peptide for Gus (45) nor
on the efficiency of Vas-Fsn::HA coimmunoprecipitation (Fig.
1H, lane 7). Taken together, these results show that the
DINNN motif in Vas is important for its interaction with the
B30.2/SPRY domain of Fsn.
In equivalent experiments with GusL::HA we observed qual-
itatively similar but significantly weaker inhibitory effects for
these peptides (Fig. 1I). This confirms previous observations
(44, 45) that the DINNN motif is important for the interaction
between Gus and Vas, but, importantly, it also indicates that
Gus, unlike Fsn, may also associate with Vas through additional
contacts. As full-length Vas and a DINNN motif containing pep-
tide bind to Gus equally well in vitro (44), these additional con-
tacts are likely stabilized in vivo by other molecules.
We also investigated the role of the B30.2/SPRY domains of
Gus and Fsn on Vas interaction by examining the effect of
mutating W221 of Gus, a residue of the B30.2/SPRY domain,
which when altered to Leu greatly reduced the interaction of
Gus with a Vas-derived peptide containing the DINNN motif
(44). Consistent with this, GusL::HA carrying the W221L sub-
stitution (GusL::HAW221L) coimmunoprecipitated less effi-
ciently with Vas than wild-type GusL::HA. However, this mu-
tation did not fully abrogate association with Vas (Fig. 1J),
again suggesting that interactions other than those between the
B30.2/SPRY domain of Gus and the DINNN motif of Vas
contribute to the interactions of the two full-length proteins.
We performed the equivalent experiment for Fsn by substitut-
ing Y239 (45) with Ala, and found that Fsn::HAY239A did not
immunoprecipitate with Vas at detectable levels (Fig. 1K).
This indicated that the interaction between the B30.2/SPRY
domain of Fsn and the DINNN motif of Vas are largely re-
sponsible for the Fsn::HA-Gus association.
Molecular genetics of gus and Fsn. We next addressed the
function of Gus and Fsn during oogenesis. Based on the phe-
notype of a mutant allele (gusZ409), gus was previously impli-
cated in localizing Vas to the posterior of the oocyte (37). We
and others, however, found during subsequent work that the
gusZ409 chromosome, which was recovered from a chemical
mutagenesis screen (14), contains at least two additional mu-
tations that affect female fertility and embryonic patterning,
including an allele of Bicaudal-C. Because of the confounding
effects of these additional mutations, we obtained fully inde-
pendent gus alleles for this study.
Expressed sequence tag (EST) evidence predicts six gus
mRNAs, five transcribed from a common proximal promoter
(gus-RA and gus-RC through gus-RF; the “RA class”) and one
(gus-RB) from a second promoter approximately 10 kb up-
stream (FlyBase) (Fig. 2A). We used RT-PCR to show that
both the RA class and gus-RB are expressed in ovaries (Fig.
2B). All annotated gus mRNAs possess an ORF of 281 amino
acids whose start codon resides in an exon common to all
transcripts, but all except gus-RF also contain an upstream
in-frame AUG and could thus encode longer protein isoforms
with different N-terminal regions. We raised two polyclonal
antibodies against recombinant Gus to test which of the puta-
tive isoforms are expressed in ovaries. When interrogating
Western blots with these antibodies, we detected a band of
approximately 30 kDa that is reduced in ovaries bearing the
gusf07073 allele (see below), which likely corresponds to the
281-amino-acid protein (Fig. 2C). We did not reproducibly
detect any bands that correspond to a longer Gus isoform. This
is consistent with our previous observation that an antibody
raised against the unique N-terminal part of Gus did not show
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immunoreactivity on Western blots (37). However, these neg-
ative data cannot rule out that small amounts of one or more
longer isoforms of Gus are expressed.
For this reason, we prepared HA-tagged transgenic proteins
corresponding to the 281-amino-acid Gus protein (GusS::HA)
as well as to the 349-amino-acid protein (GusL::HA) that
could be produced by gus-RA using its upstream AUG for
functional studies. Notably, both GusL::HA (Fig. 1) and
FIG. 2. Molecular genetics of gus and Fsn. (A) Schematic representation of the gus locus and its transcripts (not to scale). Insertion sites of the
PBac elements used in this study are indicated. (B) RT-PCR amplifications specific for the RA class and gus-RB transcripts indicate that both
mRNAs are expressed in wild-type ovaries (lane A). gusf07073 impairs expression of all tested transcripts (lane B), while guse00456 in trans to gusf07073
(lane C) or homozygous (lane D) affects only gus-RB. Positions of the primer pairs used are indicated in panel A; exact sequences are available
upon request. A fragment of cul-1 mRNA was amplified as a control. (C) An antibody raised against recombinant Gus recognizes a 30-kDa
protein that is reduced in gusf07073 ovaries, corresponding most likely to the 281-amino-acid-long isoform of Gus (GusS). The blot was also probed
with anti--tubulin antibodies (-Tub) as a loading control. (D) Transgenic GusS::HA efficiently coimmunoprecipitates Vas. A peptide containing
an intact DINNN motif moderately interferes with this reaction, while a corresponding peptide bearing the N188A substitution within the DINNN
motif does not have this effect. (E) Eyes from flies bearing the gusf07073, guse00456, and gusf04367 insertions. The mini white marker that tags the PBac
shows position effect variegation in its expression. (F) In trans to the deficiency Df(2R)nap1, the gusf07073, guse00456, and gusf04367 mutations cause
defects in the wing, including blisters, folded wings and ectopic vein material. (G) Hoyer’s embedded wings derived from Df(2R)nap1/gusf07073 flies.
(H) Schematic representation of the Fsn locus (not to scale). The insertion site of PBac Fsnf06595 is indicated. (I) RT-PCR amplifications specific
for the Fsn-RA and Fsn-RB transcripts indicating expression of both isoforms in wild-type ovaries (lane A). In Df(2R)Exel7124/Fsnf06595 ovaries
(lane B) these mRNAs are not expressed at detectable levels. (J) Eggs produced by gusf07073/gusf07073 mothers. Many of these eggs collapse.
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GusS::HA (Fig. 2D) associated with Vas in coimmunoprecipi-
tation experiments. The interactions of either isoform with Vas
were similarly sensitive to competition by a peptide bearing an
intact DINNN motif and insensitive to the N188A-containing
peptide (Fig. 1H and 2D). Therefore, the short and predicted
long isoforms of Gus appear to have a similar capability to
interact with Vas.
Several alleles of gus were recovered from a large-scale ge-
netic screen (39). gusf07073 is a PiggyBac (PBac) insertion into
the first intron of all annotated gus transcripts, which largely
abrogates expression of all gus mRNAs (Fig. 2B). gusf04367 and
guse00456 are PBac insertions proximal to the first exon of
gus-RB. guse00456 reduces expression of gus-RB but not of RA
class-specific products (Fig. 2B). We did not quantitate gus
expression levels in gusf04367 mutant flies. We verified the PBac
insertion sites in these alleles by genomic PCR experiments
using combinations of PBac and gene-specific primers (not
shown) and noted that the mini-white marker of PBac showed
variegated expression (Fig. 2E), consistent with the position of
gus and thus the PBac insertion sites, near the euchromatin-
heterochromatin junction (36). Finally, all three insertions
cause obvious and similar wing morphology phenotypes, in-
cluding blistering, formation of ectopic vein material, and loss
of material at the margin (Fig. 2F and G), usually affecting only
one wing. These phenotypes occur at low penetrance in
guse00456/Df(2R)nap1, gusf04367/Df(2R)nap1, and gusf07073/
gusf07073 flies but are frequent in gusf07073/Df(2R)nap1 flies
[Df(2R)nap1 is a deletion mutation of a chromosomal region
that includes gus]. Taken together, these data indicate that all
three mutant strains contain bona fide mutations of gus.
The Fsn locus is less complex. We confirmed expression of
two mRNAs, Fsn-RA and Fsn-RB, in ovaries. These mRNAs
differ slightly in their 5 untranslated regions (UTRs) but en-
code identical proteins of 255 amino acids (Fig. 2H and I). The
PBac insertion Fsnf06595 is inserted in a sequence common to
the 5 UTRs of the two transcripts and abrogates expression of
both mRNAs (Fig. 2I) (46).
gus is a maternal effect gene. We tested whether gus and Fsn
mutant mothers produce defective eggs or embryos. gusf07073/
gusf07073 or gusf07073/Df(2R)nap1 embryos (for simplicity we
refer to embryos by their maternal genotype) hatched only
rarely (Table 1), and most viable embryos were produced by
young females. guse00456/guse00456 embryos also rarely hatched;
however, in trans to stronger alleles [Df(2R)nap1 or gusf07073]
this allele has little effect on embryonic viability. This indicates
either that guse00456 acts as a gain-of-function allele or that the
chromosome carries a second site mutation. gusf04367 can be
maintained as a homozygous stock, and most embryos hatch
into viable larvae; thus, it is a very weak allele. For further
work we concentrated on gusf07073, as both molecular and phe-
notypic evidence indicate that it most closely approximates a
simple null allele.
Most gusf07073/gusf07073 or gusf07073/Df(2R)nap1 embryos desic-
cate and collapse soon after egg laying (Fig. 2J; Table 1). This
phenotype was nearly fully rescued by maternal overexpression
of GusS::HA using the ubiquitous Act5C-Gal4 driver, but not
when the germ line-specific nanosGal4::VP16 (nosGal4) driver
was used (41). This most likely reflects a requirement for gus in
somatic follicle cells, although effects from the promoters driv-
ing different amounts of gus expression in germ line cells can-
not be entirely ruled out. Unlike GusS::HA, GusL::HA did not
rescue the collapsed-egg phenotype; in fact, gusf07073/gusf07073
flies containing both the GusL::HA transgene and the Act5C-
Gal4 driver were never recovered, suggesting that GusL::HA,
expressed at high levels in gusf07073/gusf07073 somatic cells, is
lethal. Df(2R)Exel7124/Fsnf06595 [Df(2R)Exel7124 is a chromo-
TABLE 1. Gus maternally affects embryonic viability
Maternal genotype Total no. of embryos scoredfor hatching frequency
% Hatched
embryos
Total no. of embryos scored
for collapsed phenotype
% Collapsed
embryos
Oregon-R 6,851 92.8 3,597 0
	/gusf07073 2,561 94.3 1,214 0
	/guse00456 2,679 92.4 1,236 0
	/gusf04367 1,193 97.4 1,193 0
	/Df(2R)nap1 1,892 85.6 NDa
gusf07073/guse00456 2,890 74.8 1,529 0.2
guse00456/gusf07073 1,522 80.6 1,522 0.6
gusf07073/gusf07073 4,543 2.3 3,127 68.1
guse00456/guse00456 4,071 5.5 2,495 2.7
gusf07073/Df(2R)nap1 2,710 9.2 1,413 76.9
guse00456/Df(R2)nap1 1,536 73.8 1,536 1.2
gusf04367/Df(2R)nap1 2,109 70.4 2,109 1.1
gusf07073/gusf07073; actGal4/TM3Sb 526 0.6 526 88.4
gusf07073/gusf07073; TM3Sb/Gus(S)::HA 853 0.9 853 86.3
gusf07073/gusf07073; Gus(S)::HA/TM3Sb 799 0.3 799 91.9
gusf07073/gusf07073; Gus(S)::HA/nosGal4 1,801 0.6 1,801 93.7
gusf07073/gusf07073; actGal4/Gus(S)::HA 1,670 20.1 1,670 2.8
gusf07073/gusf07073; Fsn::HA/TM3Sb 87 1.1 87 81.6
gusf07073/gusf07073; Fsn::HA/actGal4 1,135 14.2 1,135 47.3
Fsnf06595/	 394 88.5 394 0
	/Df(2R)Exel7124 393 93.2 393 0
Fsnf06595/Df(2R)Exel7124 657 76.7 657 0
	/cul-5EY21463 877 90.3 877 1.0
cul-5EY21463/cul-5EY21463 1,805 5.9 1,805 62.3
a ND, not determined.
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somal deletion that includes Fsn] embryos have nearly wild-
type viability. Intriguingly, Fsn::HA driven by Act5C-Gal4
could partially rescue the collapsed-egg gusf07073 phenotype.
Fsn and Gus can modulate Vas levels in ovaries and interact
with Cul-1 and Cul-5, respectively. The predicted function of
Fsn and Gus as E3 ligase receptor subunits suggests that they
may modulate Vas abundance by recruiting it to Cul-1 and
Cul-5-containing CRL complexes, respectively. To accurately
compare Vas levels in ovarian extracts from different geno-
types, we produced Western blots from 96-well E-PAGE gels
incubated in duplex with primary rabbit anti-Vas and mouse
anti--tubulin antibodies, which we then detected with fluo-
rescently labeled secondary antibodies. This allowed us to si-
multaneously test multiple replicates of each extract on the
same gel under identical conditions. We took care to use only
flies of comparable age, with ovaries of similar size and a
similar distribution of egg chamber stages, for these compari-
sons (see Materials and Methods for details).
Using these methods, we found a consistent and statistically
significant reduction of Vas levels to 58.2%  16.2% of that of
the wild type upon nosGal4-driven overexpression of Fsn::HA
(Fig. 3A). Importantly, this requires direct interaction between
Fsn::HA and Vas, as the effect was much smaller and not
statistically significant (83.7%  27.1%) when we overex-
pressed Fsn::HAY239A. We observed similar reductions in Vas
levels upon nosGal4-driven overexpression of GusL::HA or
GusS::HA (51.6%  13.9% and 56.8%  15.7% of wild-type
control levels, respectively). Thus, we conclude that overex-
pression of either Fsn or Gus destabilizes Vas. We next ana-
lyzed extracts prepared from gus or Fsn mutant ovaries. Con-
sistent with our overexpression data, we observed a statistically
significant increase in overall Vas levels to 123.2%  22.6% in
Df(2R)Exel7124/Fsnf06595 ovaries. We did not observe a statis-
tically significant change in Vas levels in gusf07073/gusf07073 ova-
ries (92.1%  22.8%). However, Vas levels were further re-
duced in gusf07073/gusf07073 ovaries overexpressing Fsn::HA
(41.5%  6.6% versus 58.2%  16.2%; P 
 0.0001).
To directly test whether Fsn is associated with ubiquitin E3
ligase complexes, we probed immunoprecipitates of Fsn::HA
and Gus::HA for Cul-1. Cul-1 associated with Fsn::HA, but not
with Gus::HA (Fig. 3B), corroborating the idea that Fsn acts as
a substrate recognition subunit of a Cul-1 E3 ligase. Notably,
we observed this interaction only in low-stringency buffers and
not in mRIPA buffers (see Materials and Methods). Fsn
interacts with Skp proteins in yeast two-hybrid assays (7, 35),
further supporting the conclusion that Fsn is a subunit of a
Cul-1 CRL.
We next probed immunoprecipitates of Fsn::Ha and Gus::HA
for the presence of Cul-5. As expected, we found that Cul-5
associates with Gus::HA, but not with Fsn::HA (Fig. 3B), in-
dicating that Gus most likely acts as a substrate receptor for a
Cul-5-containing ubiquitin E3 ligase complex. Furthermore,
Gus and the EloBC complex associate stably through several
purification steps and have been cocrystallized (44). They also
interact in yeast two-hybrid screens (7, 35). Human SSB1, a
likely orthologue of Gus that is 69% identical in sequence,
interacts with Cul-5 (11). Lastly, we found that females ho-
mozygous for the cul-5EY21463 mutation, a viable P-element
insertion that reduces cul-5 mRNA and Cul-5 protein levels
(31), produce mostly collapsed embryos which resemble those
produced by gusf07073/gusf07073 mutants (Table 1), further sup-
porting the idea that Gus and Cul-5 act together.
Endogenous Fsn and Gus fine-tune posterior Vas deploy-
ment. We next asked whether genetic manipulations of Fsn-
and gus-dependent pathways affect Vas localization. Immuno-
stainings revealed that Vas accumulates both in the nurse cell
perinuclear nuage and oocyte pole plasm in gus and Fsn mu-
tants and upon Gus or Fsn overexpression (see Fig. S2 in the
supplemental material). Notably, however, from individual im-
ages we observed that posterior accumulation of GFP::Vas
appeared premature in Fsn mutant oocytes (Fig. 3C to F). To
address this quantitatively, we scored the percentage of wild-
type and Fsn oocytes that showed posterior GFP::Vas accu-
mulation as a function of the anterior-posterior length of the
oocyte divided by the length of the germ line cyst (Fig. 3G). We
found obvious posterior GFP::Vas accumulation in 55% of the
Fsn mutant oocytes that were between 20 and 24% cyst length
(corresponding to stage 8 [34]), while we observed this in only
4.3% of equally staged wild-type egg chambers. As Vas and
Fsn directly interact, this, taken together with the immunoblot-
ting data discussed above, indicates that Vas is stabilized and
accumulates prematurely in the pole plasm when Fsn activity is
reduced.
We observed little effect of gusf07073 on posterior Vas de-
ployment. This is contrary to previous results indicating that
Vas failed to stably accumulate in the pole plasm of gusZ409
mutants (37). While posterior Vas does appear reduced in
some gusf07073 oocytes, variability among individual oocytes,
and ambiguity in strictly delineating the pole plasm for quan-
titation purposes, prevented us from drawing a firm conclusion
in this regard. However, when we sensitized the gusf07073/
gusf07073 mutant background by introduction of a single copy of
the cul-5EY21463 allele we observed a notable delay in posterior
accumulation of Vas (Fig. 3H and I). Nearly 40% of gusf07073/
gusf07073; cul-5EY21463/TM3 oocytes that were between 35 and
39% of the cyst length had not accumulated posterior Vas, while
all control oocytes (wild type, gusf07073/gusf07073, or cul-5EY21463/
TM3) of a similar stage had done so (Fig. 3J). We attempted to
extend this analysis to gusf07073/gusf07073; cul-5EY21463/cul-5EY21463 in-
dividuals, but found that these females produce mostly aber-
rant egg chambers with numerous defects (18), precluding the
possibility of comparison.
Maternal manipulation of Gus- and Fsn-dependent path-
ways influences PGC formation. Primordial germ cell (PGC)
counts are a sensitive bioassay for Vas activity (2, 10, 21).
Consistent with our observation that ovaries overexpressing
Fsn::HA have clearly reduced Vas levels, we found that em-
bryos from Fsn::HA-overexpressing females form fewer PGCs
than do wild-type embryos (an average of 17 versus 34) (Table
2). This effect was enhanced when one genetic dose of vas was
removed; embryos from vasPD/	 or vasPH165/	 females have
32 PGCs on average, but they have only 10 to 12 when Fsn::HA
is overexpressed. Importantly, overexpression of the Fsn::
HAY239A mutant has a much less dramatic impact; such em-
bryos form an average of 27 PGCs, despite an expression level
similar to that of Fsn::HA (Fig. 1K). Reducing endogenous
Fsn by introducing Fsnf06595 or Df(2R)Exel7124 into the ma-
ternal Fsn::HA overexpression background suppresses the loss
of PGCs in a statistically significant manner (average of 22
PGCs versus 17). Introducing both Fsn mutant chromosomes
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FIG. 3. Effects of manipulations of gus- and Fsn-dependent pathways on Vas in ovaries. (A) Relative amount of Vas in ovaries normalized to the
-tubulin signal. Bar 1 shows a comparison of an Oregon-R wild-type extract to itself and bar 2 shows a comparison of an Oregon-R extract to three
independently prepared Oregon-R wild-type extracts. Bars 3 to 10 show comparisons of extracts from the following genotypes to Oregon-R: vasPD/
vasPH165 (bar 3), GusL::HA/nosGal4 (bar 4), GusS::HA/nosGal4 (bar 5), gusf07073/gusf07073 (bar 6), gusf07073/gusf07073; Fsn::HA/nosGal4 (bar 7),
Fsn::HA/nosGal4 (bar 8), Fsn::HAY239A/nosGal4 (bar 9), and Fsnf06595/Df(2R)Exel7124 (bar 10). (B) Cul-1 is found in Fsn::HA but not Gus::HA
immunoprecipitates. Conversely, Cul-5 associates with Gus::HA but not with Fsn::HA. (C to F) Examples in which posterior GFP-Vas is not apparent
in wild-type oocytes (C and E) but is faint (D) or obvious (F) in smaller, earlier-stage Fsn mutant oocytes. (G) Correlation between posterior GFP::Vas
accumulation and the ratio of oocyte to germ line cyst length. Posterior GFP::Vas is detectable in smaller Df(2R)Exel7124/Fsnf06595 oocytes (columns B)
than in the wild type (columns A) (n  74 for the wild type; n  90 for Fsn). (H and I) Stage 10 oocytes of wild-type females and gusf07073/gusf07073;
cul-5EY21463/TM3Sb females immunostained for Vas. F-actin is labeled with rhodamine phalloidin. No posterior enrichment of Vas is evident in the
mutant oocyte. (J) Correlation between posterior Vas enrichment and the ratio of oocyte to germ line cyst length. Genotypes represented by the columns
are Oregon-R (A), gusf07073/gusf07073 (B), cul-5EY21463/TM3Sb (C), and gusf07073/gusf07073; cul-5EY21463/TM3Sb (D). Posterior Vas accumulation is delayed
in gusf07073 homozygotes sensitized by introduction of a cul-5 P-element insertion (n  63 for the wild type; n  66 for gusf07073/gusf07073; n  55 for
cul-5EY21463/TM3Sb; n  55 for gusf07073/gusf07073; cul-5EY21463/TM3Sb).
1776
 o
n
 M
ay 7, 2015 by PO
STECH LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
causes an even stronger suppression (25 PGCs). These results
support the argument that endogenous Fsn contributes to the
overexpression phenotypes and, taken together with the pro-
tein quantitation and affinity data described above, strongly
support the idea that endogenous Fsn regulates Vas stability
during oogenesis, destabilizing it through a direct interaction.
Fsn mutant embryos did not form extra PGCs (34 versus 34)
(Table 2). Consistent with this, overexpression of GFP::Vas
from transgenes that rescue vas mutant phenotypes also did
not lead to the formation of additional PGCs. This indicates
that while reducing maternal vas reduces the number of PGCs,
additional Vas is not sufficient to cause elevated PGC num-
bers, or the threshold of additional Vas for doing so was not
reached in our experiments.
In similar experiments with Gus, we found that maternal
overexpression of either GusL::HA or GusS::HA caused a
significant reduction in the number of PGCs, consistent with
the reduced amount of Vas we observed in the corresponding
ovaries (19 to 22 PGCs versus 34) (Table 2). The majority of
Gus:HA-overexpressing embryos developed normally and had
only rare displaced Vas-positive cells, as are also observed in
wild-type embryos. However, some eggs produced from Gus:
HA-overexpressing females were unfertilized, and some em-
bryos developed aberrantly and had scattered Vas-positive
cells in ectopic sites. We only scored PGCs from the class that
apparently developed normally. gusf07073/gusf07073 embryos that
did not collapse (see above) were frequently unfertilized or
sometimes developed aberrantly with scattered Vas-positive
cells; those that were morphologically normal and could be
scored also displayed a significant reduction of PGCs in com-
parison to wild-type or 	/gusf07073 control embryos (21 versus
34 or 35, respectively) (Table 2). Expression of Gus under the
control of Act5C-Gal4 rescued the collapsed-egg phenotype
and had little effect on the number of PGCs formed by	/gusf07073
embryos (32 versus 35). However, gusf07073/gusf07073; GusS::HA/
Act5C-Gal4 embryos formed only 23 PGCs on average, corrob-
orating the idea that gus is required maternally in the germ line,
not the soma, for efficient PGC formation.
The reduced number of PGCs in gus mutant embryos is
consistent with a positive regulatory function of Gus for Vas in
the pole plasm, as is the delay in posterior Vas deployment in
gusf07073/gusf07073; cul-5EY21463/TM3 oocytes. However, this
conclusion is inconsistent with the Gus overexpression data.
We propose that while ectopic, overexpressed Gus can pro-
mote ubiquitin-mediated Vas degradation, in the pole plasm
TABLE 2. Average no. of PGCs per embryo derived from mothers of the indicated genotypesi
Maternal genotype Total no. ofembryos
Avg no. of
PGCs/embryo SD
P
Oregon-Ra Transgeneb
Oregon-R 60 34.33 4.02 NA
	/vasPD 50 32.58 4.29 
0.05
	/vasPH165 50 31.68 4.47 
0.05
	/	; GFP::Vas(wt1)/GFP::Vas(wt2) 47 32.30 3.89 
0.05
nosGal4/Fsn::HA(6.11) 195 17.01 3.57 
0.0001
nosGal4/Fsn::HA(6.15) 69 16.81 3.43 
0.0001
nosGal4/Fsn::HA(6.18) 130 17.52 3.96 
0.0001
	/vasPD; nosGal4/Fsn::HA(6.15) 64 11.97 3.05 
0.0001
	/vasPH165; nosGal4/Fsn::HA(6.15) 63 10.67 3.98 
0.0001
nosGal4/Fsn::HAY239A(24.7) 53 27.72 3.75 
0.0001 
0.0001c
nosGal4/Fsn::HAY239A(24.10) 53 27.49 4.13 
0.0001 
0.0001c
Fsnf06595/	; nosGal4/Fsn::HA(6.11) 123 21.72 4.11 
0.0001 
0.0001c
	/Df(2R)Exel7124; nosGal4/Fsn::HA(6.11) 64 21.94 3.03 
0.0001 
0.0001c
Fsnf06595/Df(2R)Exel7124; nosGal4/Fsn::HA(6.11) 64 24.95 3.63 
0.0001 
0.0001c
Fsnf06595/Df(2R)Exel7124 51 34.33 5.77 NSd
	/Df(2R)Exel7124; nosGal4/Fsn::HA(6.15) 63 22.76 3.57 
0.0001 
0.0001e
Fsnf06595/Df(2R)Exel7124; nosGal4/Fsn::HA(6.18) 44 25.39 5.37 
0.0001 
0.0001f
	/gusf07073 55 35.44 4.73 NSd
gusf07073/gusf07073 83 21.12 8.49 
0.0001
cul-5EY21463/cul-5EY21463 49 25.00 5.52 
0.0001
nosGal4/Gus(S)::HA(5.3) 63 20.40 4.05 
0.0001
nosGal4/Gus(S)::HA(5.5) 110 19.22 3.97 
0.0001
nosGal4/Gus(L)::HA(4.6) 147 22.35 4.65 
0.0001
nosGal4/V::GusS(2.11) 41 24.54 4.32 
0.0001
nosGal4/Gus(L)::HAW221L(17.1) 56 28.34 4.34 
0.0001 
0.0001g
nosGal4/Gus(L)::HAW221L(17.4) 52 28.63 3.71 
0.0001 
0.0001g
gusf07073/CyO; GusS::HA/act5C-Gal4 50 31.80 5.16 
0.01
gusf07073/gusf07073; GusS::HA/act5C-Gal4 55 22.64 4.14 
0.0001 NSh
a P value calculated in comparison to the Oregon-R sample.
b P values calculated in comparison to the relevant reference transgene as indicated below.
c Compared to nosGal4/Fsn::HA(6.11).
d Difference not statistically significant in comparison to Oregon-R.
e Compared to nosGal4/Fsn::HA(6.15).
f Compared to nosGal4/Fsn::HA(6.18).
g Compared to nosGal4/GusL::HA(4.6).
h Difference not statistically significant in comparison to gusf07073/gusf07073.
i Numbers in parentheses after genotypes denote independent transgene insertions. NA, not applicable; NS, not statistically significant.
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endogenous Gus functions in a stabilizing role or as a positive
regulator of Vas activity.
Like gusf07073/gusf07073 eggs, cul-5EY21463/cul-5EY21463 eggs
often collapsed and were not fertilized, and some cul-5EY21463/
cul-5EY21463 embryos developed aberrantly with scattered Vas-
positive cells. Similar to gusf07073/gusf07073 embryos, those that
were morphologically normal averaged only 25 PGCs (Table
2). The similarity between gus and cul-5 mutant phenotypes
further corroborates the idea that Gus and Cul-5 act together
during oogenesis to promote PGC formation.
Gus and Fsn accumulate in overlapping but distinct pat-
terns. To assess the subcellular distribution of Fsn and Gus in
ovaries, we prepared flies that express Venus-tagged forms of
Gus and Fsn (V::GusS; V::GusL and V::Fsn, respectively) un-
der nosGal4 control. The expression pattern of V::GusS essen-
tially recapitulates earlier results for endogenous Gus (37). In
the nurse cells through stage 8, V::GusS accumulates at high
levels surrounding the nurse cell nuclei and in punctate aggre-
gates throughout the cytoplasm (Fig. 4A). We also observed
some cortical enrichment of these aggregates. In early oocytes,
V::GusS forms a particulate pattern throughout the ooplasm
and is also cortically enriched (Fig. 4A). We also noted some
nuclear V::GusS in both nurse cells and the oocyte. At stage 10,
the signal surrounding the nurse cell nuclei becomes weaker and
the particulate nature of the cytoplasmic aggregates becomes less
pronounced (Fig. 4B). Importantly, V::GusS is enriched in the
posterior of the oocyte at stage 10, indicating that Gus is
indeed a pole plasm component. In later stages, posterior
V::GusS diminishes (Fig. 4C) and is not detectable in early
embryos. Importantly, posterior V::GusS accumulation re-
quires vas. In vasPD/Df(2L)A267 [Df(2L)A267 is a chromo-
somal deletion that includes vas] mutant egg chambers, cortical
V::GusS remains detectable, but the posterior enrichment is
clearly lost (Fig. 4D). The distribution of V::GusL is indistin-
guishable from that of V::GusS (data not shown).
When expressed with the nosGal4 driver, V::Fsn is enriched
in the nuclei of both nurse cells and oocytes (Fig. 4E to G).
Unlike V::Gus, V::Fsn does not accumulate in the perinuclear
region of nurse cells, although we observed some cortical accu-
mulation in mid- to late-stage oocytes. V::Fsn is recruited to the
pole plasm of mid- to late-stage oocytes (Fig. 4F to H); however,
this enrichment is later lost (Fig. 4I). In mature eggs V::Fsn is
present at high levels throughout the ooplasm (Fig. 4I). Posterior
accumulation of V::Fsn also requires vas (Fig. 4J).
Vas lacking the DINNN motif accumulates to high levels
and efficiently rescues vas phenotypes. To test how Vas would
be affected by a mutation that impairs its association with Gus
and Fsn, we compared the distribution of a wild-type GFP-Vas
fusion with a counterpart that had the DINNN motif substituted
by five Ala residues [GFP::Vas(wt) and GFP::Vas(5xAla), respec-
tively]. Many similar constructs with the same promoter (vas)
that produced wild-type or other mutant forms of Vas (Fig. 5A
and data not shown) (10) express protein at levels much lower
than endogenous Vas. In contrast, many independent trans-
formant lines for GFP::Vas(5xAla) expressed the protein at
very high levels (Fig. 5B), suggesting that the substitution of
five Ala residues might stabilize Vas. The distribution of
GFP::Vas(5xAla) reproduces the wild type, although it clearly
accumulates at higher levels in the nuage, pole plasm, and
PGCs (Fig. 5C to F). We next quantitated transgenic protein
and RNA levels through quantitative Western blot analyses
and qRT-PCR experiments (Fig. 5G and H, respectively, and
data not shown). When comparable levels of the two trans-
genic mRNAs were expressed, the mutant form of GFP::Vas
accumulated to about 1.5 times the level of the corresponding
wild-type protein. This suggests that the substitution of five Ala
residues has a stabilizing effect on Vas, GFP::Vas(5xAla) res-
cues PGC formation in vasPD/vasPH165 embryos more effi-
ciently than GFP::Vas(wt) (Fig. 5I), and either transgene res-
cues viability of vasPD/vasPH165 embryos (Fig. 5J). We conclude
that the substitution of five Ala residues enhances Vas stability
and increases its biological activity. As our competition ex-
periments indicate that the binding of Fsn to Vas is more
sensitive to the DINNN motif than that of Gus, this is
consistent with the conclusion that Fsn, but not Gus, is a
negative regulator of Vas.
DISCUSSION
Full accumulation of Vas in the pole plasm requires the
activity of Faf, a DUB, indicating that Vas is regulated in the
oocyte posterior through ubiquitin-dependent pathways (25).
Our study identifies two CRL receptors, Fsn and Gus, as ad-
ditional regulators of Vas. Our biochemical and genetic data
suggest that Fsn and Gus act by directly recruiting Vas to their
respective CRL complexes, and both proteins accumulate to-
gether with Vas in the pole plasm.
Fsn is clearly a negative regulator of Vas, presumably tar-
geting it via Cul-1 for proteasomal-mediated degradation. In
Fsn mutant ovaries, we observed increased Vas, and Fsn over-
expression produces the reciprocal effect. Furthermore, reduc-
tion of endogenous Fsn suppresses the Fsn overexpression
phenotype, indicating that the endogenous protein acts in the
same direction as the one we expressed ectopically. We also
observed precocious accumulation of Vas expression in the
posterior of Fsn mutant oocytes, demonstrating that endoge-
nous Fsn antagonizes Vas accumulation. Taken together, these
findings are consistent with a role for endogenous Fsn in pro-
moting Vas degradation.
The function of Gus in regulating Vas, however, is more
complex, as its overexpression and mutant phenotypes are
pleiotropic and not reciprocal. In a gus mutant background
where cul-5 dosage is also reduced, posterior Vas accumula-
tion is delayed, the opposite of what we observed in Fsn mutant
ovaries. Consistent with this, reduction of gus enhances the
effects of Fsn overexpression on Vas levels. Taken together
with our molecular experiments, which indicate that Gus and
Fsn cannot bind simultaneously to the DINNN motif of Vas,
these data support a conclusion that endogenous Gus is a
positive regulator of Vas, acting antagonistically with Fsn to
establish a steady state of Vas ubiquitination that allows timely
posterior Vas accumulation and full activity. We believe that
these loss-of-function data more accurately reflect the function
of endogenous gus and that Gus overexpression might alter its
activity, perhaps by favoring conjugation of destructive long
ubiquitin chains rather than that of short activating ones
and/or by impacting other regulators of Vas, as E3 ligases and
DUBs often cross-regulate each other (28).
Gus and Fsn could catalyze different ubiquitination events,
with Fsn promoting Vas degradation and endogenous Gus in
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FIG. 4. V::Gus and V::Fsn accumulate in the pole plasm in a vas-dependent manner. (A to C) In a wild-type background, V::Gus driven by
nosGal4 is expressed at low levels in germ line nuclei but accumulates to high levels in the cytoplasm surrounding the nurse cell nuclei. In the germ
line cytoplasm, V::Gus is ubiquitous, but it is enriched in numerous luminous foci, particularly during the earlier stages of oogenesis. In the oocyte,
V::Gus is enriched in the cortex but accumulates in the pole plasm during stage 10. In late oocytes, posterior V::Gus levels decrease. (D) Pole plasm
accumulation of V::Gus is lost in vas mutants (compare with panel B). (E to I) V::Fsn driven by nosGal4 in a wild-type background during early
oogenesis (notice that transgene expression follows the expression pattern of the driver) (E), stage 9 (F), stage 10 (G), stage 13 (H), and stage 14
(I). V::Fsn accumulates in nuclei and is uniformly distributed throughout the nurse cell cytoplasm. In the oocyte, the protein appears cortically
enriched, and from stage 10 on, V::Fsn is enriched in the pole plasm. Posterior enrichment is not evident in mature eggs. (J) In a vas mutant
background, pole plasm accumulation of V::Fsn is lost; however, a general cortical stain is still observed. Bars, 20 mm.
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FIG. 5. GFP::Vas lacking the DINNN motif accumulates to high levels, localizes normally, and rescues vas phenotypes. (A and B) Western blots
of ovarian extracts showing expression levels of individually established lines for GFP::Vas(wt) (A) and GFP::Vas(5xAla) (B) transgenes (upper
band) and endogenous Vas (lower band). (C to F) Wild-type GFP::Vas (C) and a mutant form lacking the DINNN motif (E) localize similarly
during oogenesis. Both transgenic proteins rescue PGC formation in vas mutant embryos. Bars, 20 mm. (G and H) GFP::Vas(5xAla) accumulates
to higher levels than GFP::Vas(wt). (G) Normalized expression levels of the mutant protein in comparison to wild type. (H) RNA expression levels
assayed by qRT-PCR. Bars 1 and 2 represent two independently prepared samples of vasPH165/vasPD; GFP::Vas(wt)/GFP::Vas(wt). Bars 3 and 4
represent two independent samples of vasPH165/vasPD; GFP::Vas(5xAla)/	. One copy of the mutant transgene expresses an RNA amount
comparable to two copies of the wild-type transgene. (I) One copy of the GFP::Vas(5xAla) transgene permits the formation of more PGCs in
vasPH165/vasPD embryos than two copies of GFP::Vas(wt). (J) Both constructs rescue the ability of vas embryos to hatch.
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the pole plasm promoting Vas activity while antagonizing Fsn-
dependent destabilization by rendering the DINNN motif less
accessible. Further modulation of Vas regulation may be ac-
complished through Gus-Vas interactions that are indepen-
dent of the DINNN motif, likely mediated in vivo by additional
proteins that stabilize the Gus-Vas complex through associa-
tions with other domains of Vas or that provide a bridging
mechanism to indirectly recruit Gus to Vas. Such interactions
would explain why Vas accumulates in the pole plasm despite
the presence there of Fsn.
Fsn may also be counter-balanced by Faf, which has previ-
ously been shown to stabilize Vas in the pole plasm (25). A
dynamic equilibrium among Gus, Fsn, and Faf may establish
and maintain a steady state of ubiquitination that allows stable
Vas expression and Vas activity. Excess Gus or Fsn (this study)
or loss of Faf (25) would shift this dynamic equilibrium to a
state of ubiquitination that promotes Vas degradation while, in
the absence of Gus, Vas may be more prone to Fsn-dependent
degradation.
Additional layers of complexity in the regulatory logic gov-
erning Vas ubiquitination are likely. For example, Vas can be
copurified from embryonic extracts with the E3 ligase purity of
essence (Poe) (25, 40), and vasPH165/poe03420 females produce
embryos with substantially fewer PGCs than vas or poe het-
erozygotes (22.1  4.5 versus 30.1  3.2 for poe03420/CyO; N.
Liu and P. Lasko, unpublished observation). poe is expressed
during oogenesis (36), and Vas distribution is aberrant in eggs
produced by females bearing certain poe alleles (C. Bazinet,
personal communication).
Proteins often have to be phosphorylated on particular mo-
tifs called phosphodegrons to be modified by the ubiquitina-
tion machinery (42). A C. elegans Vas homolog, GLH-1, fea-
tures a functional phosphodegron that, when phosphorylated
by the Jun N-terminal kinase (JNK) KGB-1, targets it for
proteasomal degradation (29). The KGB-1 binding site and
phosphodegron are conserved in Drosophila Vas, which can
associate with KGB-1 in vitro, suggesting that JNK-dependent
regulation of Vas might occur in flies as well (29). In C. elegans,
KGB-1-dependent GLH-1 degradation is antagonized by the
Cop9 signalosome subunit CSN-5, which regulates CRL activ-
ity by inactivating the Cullin subunit (30). In Drosophila spe-
cies, maternal csn-5 mutants produce embryonic patterning
defects that resemble those of vas mutants, and Vas shows
altered electrophoretic mobility (4). However, similar shifts in
Vas mobility also result from mutations that affect a meiotic
DNA damage response checkpoint in Drosophila oogenesis (3,
6, 13). It is believed that this pathway negatively regulates Vas
activity, at least with respect to its function in activating Grk
translation (6, 38), but it is unclear whether it influences Vas
abundance. These considerations might help explain the rela-
tively small effects of genetic manipulation of Gus and Fsn on
overall Vas levels, as the fraction of Vas that can be modified
through ubiquitination might be limited through other path-
ways that affect its phosphorylation state.
gus mutant phenotypes imply that Vas is not its only target,
as vas is required neither in follicle cells nor for wing devel-
opment. Recognition of a target by both Gus and Fsn implies
a B30.2/SPRY domain-DINNN motif interaction; consistently,
several Gus-interacting proteins recovered through genome-
wide yeast two-hybrid screens (7, 35) contain a DINNN motif
(45).
Both mammals and sea urchins possess Gus orthologues (11,
43, 47). Intriguingly, in these organisms Gus appears to be
expressed primarily in cells that do not express Vas but are
adjacent to Vas-expressing cells, leading to a hypothesis that
Gus may be involved in removing Vas from cells where it might
be detrimental (43). However, this interesting idea has not
been tested experimentally. In zebrafish, gus orthologues are,
conversely, expressed together with Vas in the germ line in
both adult testes and ovaries (23). Fsn orthologues are also
present throughout animal evolution. In the synapse they are
believed to interact with Highwire to form a ubiquitin E3 ligase
that downregulates a protein kinase, Wallenda, which in turn
restrains synaptic terminal growth (46). The C. elegans Fsn ortho-
logue, FSN-1, is not only involved in synaptogenesis (24) but has
also been recently identified as a negative regulator of germ line
apoptosis that is dependent on the p53 orthologue CEP-1 (5). It
will be interesting to unravel whether the Gus and Fsn ortho-
logues in these and other species also interact with Vas in the
same cell and to elucidate how recruitment of Vas to different E3
ligase complexes can influence Vas dynamics.
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